Related Experiment Video
Updated: Mar 10, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Abaloparatide and paclitaxel combination therapy Improves bone volume and tumor burden in Bone-Metastatic breast
Jade S Miller1,2,3,4, Jeremy F Kane1,3,5, Patricia A Ward1,2
1Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract:
•Abaloparatide is FDA-approved for osteoporosis but is not well characterized in patients with bone metastases.•Combination abaloparatide and paclitaxel reduced tumor and increased bone volume in an intratibial model of cancer in bone.•Abaloparatide alone did not impact tumor burden or bone volume in tumor limb.
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
